SCHEMBL5065448

SCHEMBL5065448

CSc1ncc2cc(-c3cccc(N)c3)c(=O)n(C)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 8/20 0.56
SRC P12931 6/20 0.49
FGFR1 P11362 6/20 0.49
FGFR2 P21802 3/20 0.49
FGFR4 P22455 3/20 0.49
FGFR3 P22607 3/20 0.49
EGFR P00533 3/20 0.49
PDGFRB P09619 3/20 0.48
PDGFRA P16234 3/20 0.48
MAPK14 Q16539 3/20 0.48
KIT P10721 2/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
WEE1 P30291 3/20 0.43
BMPR1B O00238 1/20 0.42
STK25 O00506 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21990257 0.87 ABL1 (0.53) ABL1SRCFGFR1FGFR2FGFR4
SCHEMBL4423133 0.85 SRC (0.66) ABL1SRCFGFR1FGFR2FGFR4
SCHEMBL5061333 0.85 ABL1 (0.44) ABL1SRCFGFR1EGFRRIPK2
SCHEMBL2080266 0.82 CYP1A2 (0.41) ABL1SRCFGFR1FGFR2FGFR4
SCHEMBL4283199 0.82 FGFR1 (0.45) ABL1SRCFGFR1FGFR2FGFR4
SCHEMBL5061792 0.81 ABL1 (0.67) ABL1SRCFGFR1EGFRPDGFRB
SCHEMBL5067103 0.81 SRC (0.44) ABL1SRCFGFR1FGFR2FGFR4
SCHEMBL4420167 0.81 FGFR1 (0.51) ABL1SRCFGFR1FGFR2FGFR4
SCHEMBL2081367 0.80 ABL1 (0.53) ABL1SRCFGFR1FGFR2FGFR4
SCHEMBL21990265 0.80 RIPK2 (0.53) ABL1SRCFGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 ABL1 936/4885SRC 417/4885FGFR1 577/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ABL1 936/4885SRC 417/4885FGFR1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.